700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
|Zekai Tahir Burak Women Health Educational and Research Hospital, Turkey|
|Posters & Accepted Abstracts: Gynecol Obstet (Sunnyvale)|
|Objective/Aim: The main objective of the servical screening is to have the screening by using the best method. The ideal screening method is having smear test, colposcopic biopsy and HPV DNA analysis. The aim of these studies are to conduct a detailed follow up program by using the results of the patients who had admitted to our hospital during the last 2 years and had been diagnosed cervical intraepithelial lesion. Method: During the 2 year period in between 2015-2016, smear test has been requested from 11.850 patients. 5180 of these patients are menapause patients, 1102 of these patients are being followed up by pap smear test because of Low grade SIL and their DNA analysis have been made for High risk HPV DNA (HHPV) types 16, 18, 31, 33, 35, 39, 45, 51, 56, 58, 66 and 68. The patients had colposcopy by the same Gynecolocist. In terms of statistical analysis and calculations IBM SPSS Statistics programs 21.0 version has been used and Chi-square test, Mann Withney U test and Corelation spearman Rho relation coefficient has been calculated. Results: The patients ages are determined as 50±3.2 years. Among 1102 patients, 278 are reportes as HPV (+) (270 grade I neoplasia and 8 grade II neoplasia) and the rest of the 824 patients are reported as HPV (-), 14 patients are reported grade II neoplasia and 670 patients grade I neoplasia and 140 patients are reported non neoplastic lesion. We consider that the most important and best method is pap smear (+) colposcopic biopsy for the patients who are HPV+, pap smear negative and colposcopic biopsy result is negative and we also consider that the having HPV (+) may be show (-) result.|
Sema Zergeroğlu is currently the Head of Training Project and R&D Department in Ministry of Health, General Directorate of Health Research, Ankara and the Coordinator of Cancer Research Center and Genetic Center of ZTB Women’s Health, Education and Research Hospital, Ankara. She is the Deputy Chief Physician of Biotechnological Products in Turkey and Contributions to Health Economics by Analysis of R&D Infrastructure, Ankara. She is also the President of local ethics commitee in ZTB. She has translated 2 Medical books in to Turkish, served as a Co-editor of a Turkish book. She is the author/coauthor of 3 book chapters, over 80 national and international scientific publications.
|PDF | HTML|